

Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.

NCT06752122

Status	RECRUITING
Phase	Phase 1
Sponsor	RNATICS GmbH
Enrollment	24 participants

Key Eligibility Criteria

Inclusion (30)

- Able and willing to give written informed consent.
 - Male or female aged 18 to 64 years (inclusive).
 - Women will be considered for inclusion if they are:
 - Not pregnant, as confirmed by pregnancy test (see assessment schedule), and not breastfeeding. AND
 - WOCBP must use one of the following highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly
- ... and 25 more (see full listing online)

Exclusion (21)

- Any clinically relevant abnormal findings in physical examination, clinical chemistry, hematology, urinalysis, vital signs, lung function or ECG at screening visit, which, in the opinion of the investigator, may either put the participant at risk because of participation in the study or may influence the results of the study, or the participant's ability to participate in the study.
 - Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease (asymptomatic Gilbert syndrome is allowed), renal disease, hematological disease, neurological disease, endocrine disease (stable and asymptomatic hypothyroidism with or without Hormone Replacement Therapy (HRT) is allowed) or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).
 - Having received any vaccination within the last 2 weeks before the first screening visit.
 - History or current evidence of clinically relevant allergies or idiosyncrasy to any drug or food.
 - History of allergic reactions to any active or inactive component of the study medication (including medication for bronchoscopy, e.g. salbutamol, lidocaine, midazolam or propofol).
- ... and 16 more (see full listing online)

Locations (1 total)

Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hanover, Germany

<https://clinicaltrials.gov/study/NCT06752122>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.